Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists.
about
Microwave-assisted ring closure reactions: synthesis of 8-substituted xanthine derivatives and related pyrimido- and diazepinopurinedionesRecent developments in adenosine receptor ligands and their potential as novel drugsA binding site model and structure-activity relationships for the rat A3 adenosine receptorStructure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.Quantification of the in vivo potency of the adenosine A2 receptor antagonist 8-(3-chlorostyryl)caffeine.Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs).Xanthines as adenosine receptor antagonists.Programmable nanoscaffolds that control ligand display to a G-protein-coupled receptor in membranes to allow dissection of multivalent effects.Nomenclature and classification of purinoceptors.International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an updatePast, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.Pharmacokinetic-haemodynamic relationships of 2-chloroadenosine at adenosine A1 and A2a receptors in vivo.8-(3-Isothiocyanatostyryl)caffeine Is a Selective, Irreversible Inhibitor of Striatal A(2)-Adenosine ReceptorsChemoinformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold.8-(3-Chlorostyryl)caffeine (CSC) is a selective A2-adenosine antagonist in vitro and in vivo.Structure-activity relationships for G2 checkpoint inhibition by caffeine analogs.Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's diseaseHistory and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents.Molecular Docking and Prediction of Pharmacokinetic Properties of Dual Mechanism Drugs that Block MAO-B and Adenosine A(2A) Receptors for the Treatment of Parkinson's Disease.Basolateral and apical A1 adenosine receptors mediate sodium transport in cultured renal epithelial (A6) cells.Adenosine stimulates cone photoreceptor myoid elongation via an adenosine A2-like receptor.Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranesEffects of the new A2 adenosine receptor antagonist 8FB-PTP, an 8 substituted pyrazolo-triazolo-pyrimidine, on in vitro functional modelsEvaluation of 2-benzylidene-1-tetralone derivatives as antagonists of A1 and A2A adenosine receptors.A Non-imaging High Throughput Approach to Chemical Library Screening at the Unmodified Adenosine-A3 Receptor in Living Cells.One-pot synthesis of benzofused heteroaryl azoles via tandem C-heteroatom coupling/C-H activation of azoles.In silico studies targeting G-protein coupled receptors for drug research against Parkinson's disease.Selective ligands for rat A3 adenosine receptors: structure-activity relationships of 1,3-dialkylxanthine 7-riboside derivatives.Adenosine A2AReceptors and Neuroprotection
P2860
Q21198735-2006103C-1146-467E-8714-7310C331E3DAQ27687253-9B79F549-071B-43F7-9E99-6CF278A0E4E3Q28369257-F01267DB-9783-42CC-8B0E-ED11DAE37EA1Q30424542-1358CA6A-CBE1-48AC-9399-101024123119Q33805632-36B050C5-95DA-4AEF-8119-7902E6EA0074Q33926350-081B8377-A3ED-46BD-960A-1C1921D89008Q34139398-CE02C501-7070-4213-B511-A51708BDB193Q34145241-86FF98F1-24A6-4266-AD3A-B46439C2F631Q34324355-71C65C0D-DCAB-479C-9783-46348CA95ED7Q34701303-2E5BB862-E2C9-4034-BF83-FDD8BAE139A5Q35489240-40BEBE28-CE0A-4C7C-A620-D5F7EB135466Q35873736-8F6527F1-DBBB-464A-9FAA-B2C9D4E80631Q36083177-FF9745E5-803D-4B93-A4CB-54BFAA0DBE2CQ36250876-1CCDABB8-8BB5-4843-AD75-DA0E42CDD652Q36308893-1B28C125-F337-48E4-A569-8D00E3A5AF1BQ36709879-867B89A8-CA1B-4094-AD83-525AAC7C38B3Q37358676-085C9A0E-851F-4EEF-8BCD-0877296A381FQ38395423-D627E95F-67DE-44E2-990D-8613D2EEC6B0Q39239178-A3601709-7033-4640-B029-42438DF0C5E4Q40696164-3FBB93D3-E07C-44CB-9E74-2215BEDEC34BQ41668557-507A2C0E-6636-4C85-8450-874006CA3B57Q42196443-3AF2ED02-DB46-482A-A815-9A54E9109A83Q42700371-9203D64F-4B30-463A-9F2F-12B940796FCDQ48362441-A408C0B1-2C9F-4606-BACF-784B769CE354Q49714374-F1E29E37-188A-45DC-A669-D70C113F65F9Q50523171-67A92C67-F930-4221-A7C4-4BFFE90B7CFCQ52665081-5E26B441-04F3-4C30-9C68-0BCA3FD49982Q54242505-62200C04-CC96-4923-9BAA-21381CD9520EQ56700736-4826CD0F-A0D1-4E46-8697-987BFDCFBA74
P2860
Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Structure-activity relationshi ...... lective adenosine antagonists.
@en
Structure-activity relationshi ...... lective adenosine antagonists.
@nl
type
label
Structure-activity relationshi ...... lective adenosine antagonists.
@en
Structure-activity relationshi ...... lective adenosine antagonists.
@nl
prefLabel
Structure-activity relationshi ...... lective adenosine antagonists.
@en
Structure-activity relationshi ...... lective adenosine antagonists.
@nl
P2093
P2860
P356
P1476
Structure-activity relationshi ...... lective adenosine antagonists.
@en
P2093
A van Bergen
C Gallo-Rodriguez
K A Jacobson
M Maillard
P J van Galen
P2860
P304
P356
10.1021/JM00062A005
P407
P577
1993-05-01T00:00:00Z